EFPIA seeks "soft law approach" rather than wholesale revision of EU pricing legislation
This article was originally published in SRA
Reopening the so-called "Transparency Directive" on the pricing and reimbursement of medicines must not compromise the confidentiality of pricing arrangements between pharmaceutical companies and payers, says Richard Bergström, director general of the European Federation of the Pharmaceutical Industries and Associations (EFPIA)1. Revealing details of such agreements would prevent differential pricing, he said. Mr Bergström's comments came as EFPIA responded to the European Commission's consultation on the possible review of the Transparency Directive (89/105/EEC).
You may also be interested in...
In addition to agreeing to emergency use of the Oxford University/Astra Zeneca and Sinovac vaccines, Brazil's medicines regulator has also published good manufacturing practices certificates for Pfizer and Janssen vaccine. It has questions about the Sputnik V authorization request.
A Dutch parallel registration and reimbursement pilot has brought benefits including more participation from healthcare professionals, and also forces company divisions to be less streamlined.
The UK’s withdrawal from the EU could upset the Unitary Patent Court project.